The current financial score of Spruce Biosciences Inc is 7.89. Its financial status is robust, and its operating efficiency is high.
The current valuation score of Spruce Biosciences Inc is 7.61. Its current P/E ratio is -1.50, which is -99.75% below the recent high of -0.00 and -17.71% above the recent low of -1.77.
The current earnings forecast score of Spruce Biosciences Inc is 8.75. The average price target is 147.88, with a high of 230.00 and a low of 104.00.
The current price momentum score of Spruce Biosciences Inc is 4.86. Currently, the stock price is trading between the resistance level at 62.56 and the support level at 47.09, making it suitable for range-bound swing trading.
The current institutional shareholding score of Spruce Biosciences Inc is 3.00. The latest institutional shareholding proportion is 35.22%, representing a quarter-over-quarter decrease of 20.11%. The largest institutional shareholder is James Simons, holding a total of 4.70K shares, representing 0.00% of shares outstanding, with 108.33% increase in holdings.
The current risk assessment score of Spruce Biosciences Inc is 3.41. The company's beta value is 3.18. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.